Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
RNAC Stock Forecast 2026-2027
$8.68
Current Price
$253.27M
Market Cap
Buy 8
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to RNAC Price Targets
+406.9%
To High Target of $44.00
+349.3%
To Median Target of $39.00
+84.3%
To Low Target of $16.00
RNAC Price Momentum
-8.2%
1 Week Change
-12.1%
1 Month Change
-30.7%
1 Year Change
+20.4%
Year-to-Date Change
-40.4%
From 52W High of $14.56
+55.0%
From 52W Low of $5.60
📊 TOP ANALYST CALLS
Did RNAC Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Cartesian is one of their latest high-conviction picks.
Latest RNAC Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, RNAC has a bullish consensus with a median price target of $39.00 (ranging from $16.00 to $44.00). The overall analyst rating is Strong Buy (9.8/10). Currently trading at $8.68, the median forecast implies a 349.3% upside. This outlook is supported by 8 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Julian Harrison at BTIG, projecting a 406.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RNAC Analyst Ratings
8
Buy
0
Hold
0
Sell
RNAC Price Target Range
Low
$16.00
Average
$39.00
High
$44.00
Current: $8.68
Latest RNAC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RNAC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 10, 2026 | Wedbush | Martin Fan | Outperform | Reiterates | $38.00 |
| Jun 9, 2026 | Needham | Gil Blum | Buy | Reiterates | $40.00 |
| Jun 9, 2026 | BTIG | Julian Harrison | Buy | Reiterates | $44.00 |
| May 27, 2026 | Wedbush | Outperform | Reiterates | $N/A | |
| May 26, 2026 | Needham | Buy | Maintains | $N/A | |
| May 12, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| May 1, 2026 | Wedbush | Outperform | Reiterates | $N/A | |
| Mar 10, 2026 | Wedbush | Outperform | Reiterates | $N/A | |
| Mar 9, 2026 | Cantor Fitzgerald | Overweight | Upgrade | $N/A | |
| Mar 9, 2026 | Needham | Buy | Reiterates | $N/A | |
| Jan 9, 2026 | Needham | Buy | Maintains | $N/A | |
| Nov 19, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Nov 14, 2025 | BTIG | Buy | Maintains | $N/A | |
| Jul 9, 2025 | Wedbush | Outperform | Initiates | $N/A | |
| May 8, 2025 | Needham | Buy | Maintains | $N/A | |
| Apr 9, 2025 | Needham | Buy | Reiterates | $N/A | |
| Apr 9, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 14, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Mar 13, 2025 | Needham | Buy | Reiterates | $N/A | |
| Jan 28, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A |
Cartesian Therapeutics Inc. (RNAC) Competitors
The following stocks are similar to Cartesian based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Cartesian Therapeutics Inc. (RNAC) Financial Data
Cartesian Therapeutics Inc. has a market capitalization of $253.27M with a P/E ratio of 2.0x. The company generates $1.78M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -92.9% quarter-over-quarter, while maintaining an operating margin of -33,973.1% and return on equity of +103.2%.
Valuation Metrics
Market Cap
$253.27M
Enterprise Value
$146.78M
P/E Ratio
2.0x
PEG Ratio
0.0x
Price/Sales
142.9x
Growth & Margins
Revenue Growth (YoY)
-92.9%
Gross Margin
N/A
Operating Margin
-33,973.1%
Net Margin
0.0%
EPS Growth
-92.9%
Financial Health
Cash/Price Ratio
+46.5%
Current Ratio
7.7x
Debt/Equity
-0.1x
ROE
+103.2%
ROA
-16.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Cartesian Therapeutics Inc. (RNAC) Business Model
About Cartesian Therapeutics Inc.
What They Do
Develops mRNA cell therapies for autoimmune diseases.
Business Model
The company operates as a clinical-stage biotechnology firm, utilizing its proprietary ImmTOR platform to create mRNA cell therapies that induce immune tolerance. It generates revenue primarily through the development and commercialization of its innovative therapies, with its lead product candidate, Descartes-08, currently undergoing Phase 2b trials for various autoimmune conditions.
Additional Information
Cartesian Therapeutics is based in Gaithersburg, Maryland, and focuses on addressing unmet needs in the treatment of autoimmune disorders. The company also has additional product candidates, including Descartes-15 and Descartes-33, targeting both autoimmune diseases and multiple myeloma, showcasing its commitment to advancing cell therapy solutions.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
66
CEO
Dr. Carsten Brunn Ph.D.
Country
United States
IPO Year
2016
Website
www.cartesiantherapeutics.comCartesian Therapeutics Inc. (RNAC) Latest News & Analysis
Latest News
Quick Summary
Cartesian Therapeutics granted 238,700 stock options to eight new employees at an exercise price of $10.18. The options vest over four years and have a ten-year term.
Why It Matters
The issuance of stock options to new employees can signal confidence in company growth, potentially influencing stock performance and attracting investor interest in Cartesian Therapeutics.
Source: GlobeNewsWire
Market Sentiment:
Neutral
New Strong Sell Stocks for July 1st
15 days ago
Quick Summary
CZR, RNAC, and NSP have been designated with a Zacks Rank #5 (Strong Sell) as of July 1, 2026.
Why It Matters
CZR, RNAC, and NSP being assigned a Zacks Rank #5 signals potential underperformance, indicating investors may want to reconsider their positions in these stocks.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Cartesian Therapeutics (NASDAQ: RNAC) announced an inducement award for a new employee, continuing its focus on developing cell therapies for autoimmune diseases.
Why It Matters
The inducement award signals company growth and potential talent acquisition, which can enhance innovation and drive future value, positively impacting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Cartesian Therapeutics (NASDAQ:RNAC) shares rose after the company announced a strategic licensing agreement with WestGene Biopharma.
Why It Matters
The licensing agreement may enhance Cartesian Therapeutics' growth potential and revenue streams, positively impacting investor sentiment and stock performance.
Source: Benzinga
Market Sentiment:
Positive
Quick Summary
Cartesian Therapeutics has entered a licensing agreement with WestGene to advance mRNA payloads and CAR constructs. Clinical trials are set to begin in 2H 2026, with data expected in 1H 2027.
Why It Matters
The collaboration between Cartesian and WestGene enhances mRNA technology for CAR constructs, potentially leading to significant advancements in autoimmune disease treatments, impacting stock value and investor outlook.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
The company secured $150 million in non-dilutive financing from K2 HealthVentures, with an initial $50 million tranche extending its cash runway into 2028.
Why It Matters
Securing $150 million in non-dilutive financing enhances liquidity and extends operational runway, potentially increasing company stability and growth prospects, positively impacting investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About RNAC Stock
What is Cartesian Therapeutics Inc.'s (RNAC) stock forecast for 2027?
Based on our analysis of 5 Wall Street analysts, Cartesian Therapeutics Inc. (RNAC) has a median price target of $39.00. The highest price target is $44.00 and the lowest is $16.00.
Is RNAC stock a good investment in 2027?
According to current analyst ratings, RNAC has 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $8.68. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RNAC stock?
Wall Street analysts predict RNAC stock could reach $39.00 in the next 12 months. This represents a 349.3% increase from the current price of $8.68. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cartesian Therapeutics Inc.'s business model?
The company operates as a clinical-stage biotechnology firm, utilizing its proprietary ImmTOR platform to create mRNA cell therapies that induce immune tolerance. It generates revenue primarily through the development and commercialization of its innovative therapies, with its lead product candidate, Descartes-08, currently undergoing Phase 2b trials for various autoimmune conditions.
What is the highest forecasted price for RNAC Cartesian Therapeutics Inc.?
The highest price target for RNAC is $44.00 from Julian Harrison at BTIG, which represents a 406.9% increase from the current price of $8.68.
What is the lowest forecasted price for RNAC Cartesian Therapeutics Inc.?
The lowest price target for RNAC is $16.00 from at , which represents a 84.3% increase from the current price of $8.68.
What is the overall RNAC consensus from analysts for Cartesian Therapeutics Inc.?
The overall analyst consensus for RNAC is bullish. Out of 5 Wall Street analysts, 8 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $39.00.
How accurate are RNAC stock price projections?
Stock price projections, including those for Cartesian Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 16, 2026 1:54 PM UTC